Taconic Biosciences and genOway partner to expand U.S. Access to advanced humanized mouse models. RENSSELAER, N.Y.-(BUSINESS WIRE)-Taconic Biosciences, Inc., a global leader in genetically engineered rodent models (GEMs) and humanized immune system (HIS) mouse models, today announced a strategic distribution agreement with genOway, a company specializing in the design of predictive preclinical solutions. Through the partnership, Taconic will provide U.S. researchers with access to a curated portfolio of genOway's target-specific genetically humanized mouse models. As a trusted scientific partner to drug developers, Taconic works with researchers to identify fit-for-purpose models aligned with their therapeutic area, modality, translational requirements and stage of development. The collaboration with genOway builds on this expertise by adding new target-specific models to Taconic's established portfolio and providing researchers with additional options for increasingly complex preclinical programs. "Researchers rely on Taconic not only for access to high-quality animal models, but also for the scientific expertise to help identify the right model for the questions they need to answer," said Mike Garrett, Chief Executive Officer of Taconic Biosciences. "Our partnership with genOway builds on that commitment, expanding the range of advanced humanized models we can offer U.S. researchers and helping drug developers make more informed model selections and generate data with greater translational relevance." The expanded portfolio will support research across therapeutic approaches including T-cell engagers and multispecifics, immune checkpoint and immunomodulatory therapies, Fc-mediated biologics, antibody-drug conjugates (ADCs), CAR-T therapies and other emerging modalities. U.S. customers can work directly with Taconic to discuss model availability, cohort requirements, anticipated delivery timing, therapeutic mechanism and model fit, and study-specific scientific considerations. Taconic's scientific team can also help researchers identify potentially relevant models based on the human target, therapeutic mechanism and experimental question. About Taconic Biosciences Taconic Biosciences is a global leader in genetically engineered rodent models and humanized immune system (HIS) mice, providing essential tools for immuno-oncology, immunology, neuroscience, and metabolic disease research. With more than seven decades of scientific and husbandry expertise, Taconic delivers high-fidelity models, rigorous QC, and study-ready cohorts to support translational research around the world. More News From Taconic Biosciences, Inc. RENSSELAER, N.Y. & ARCHAMPS, France-( BUSINESS WIRE )-Taconic Biosciences, Inc., a global leader in genetically engineered rodent models (GEMs) and humanized immune system (HIS) mouse models, today announced the acquisition of TransCure bioServices SAS, a leading provider of preclinical research services utilizing HIS mouse models. This acquisition enables Taconic to offer a unified global platform delivering seamless end-to-end solutions for their customers - providing humanized models, precis... RENSSELAER, N.Y.-( BUSINESS WIRE )-Taconic Biosciences, a global leader in providing disease specific rodent model solutions and related services, and Cyagen Biosciences, an AI-enabled CRO company specializing in custom genetically engineered animal and cell models for research, announced a strategic partnership to provide preclinical researchers with easier and expanded access to Cyagen's library of more than 16,000 genetically engineered mouse models. Cyagen's library of genetically engineere... RENSSELAER, N.Y.-( BUSINESS WIRE )-Taconic Biosciences has acquired the exclusive rights to a patented CRISPR-based gene editing technology for biomedical research... Taconic Biosciences, Inc. Release Versions

APOE3xARTE10 & APOE4xARTE10 APP/PS1 Alzheimer's Models. Rensselaer, N.Y. - August 3, 2026 - Taconic Biosciences, Inc., a global leader in genetically engineered rodent models and preclinical research solutions, today announced the launch of two new Alzheimer's disease (AD) mouse models that combine the well-established APP/PS1 (ARTE10) amyloid pathology model with human APOE3 and APOE4 genetic backgrounds. Together, these models provide researchers with complementary tools to investigate both familial and sporadic aspects of Alzheimer's disease biology. Alzheimer's disease remains one of the most complex neurodegenerative disorders, with multiple genetic and pathological mechanisms contributing to disease onset and progression. While many preclinical models focus on a single disease pathway, researchers increasingly rely on multiple models to better understand disease biology and evaluate potential therapeutics. The new APOE3xAPP/PS1 (ARTE10) and APOE4xAPP/PS1 (ARTE10) models address this need by combining robust amyloid pathology with clinically relevant human apolipoprotein E (APOE) genetics. APOE4 is the strongest known genetic risk factor for late-onset Alzheimer's disease, while APOE3 represents the most common human isoform and serves as an important experimental control. "Alzheimer's disease is not a single disease mechanism, and no single preclinical model can answer every research question," said Sarah Sterlace, PhD, Senior Director, Neurobiology, Portfolio Management at Taconic Biosciences. "By combining established amyloid pathology with human APOE genetics, these new models give researchers additional tools to evaluate therapeutic efficacy across more clinically relevant disease biology." The complementary models enable researchers to: * Compare therapeutic responses across different human APOE genotypes. * Investigate interactions between amyloid pathology and genetic risk factors. * De-risk potential therapeutics by using models that reflect both familial and sporadic Alzheimer's disease biology. * Strengthen confidence in preclinical findings through comparative study designs. APOExAPP/PS1 (ARTE10) Platform Evaluate amyloid pathology, plaque-associated glial response, and APOE genotype effects using APOE3xARTE10 and APOE4xARTE10 human APOE APP/PS1 Alzheimer's disease models. The new models further expand Taconic's growing neurobiology portfolio, providing researchers with access to a broad range of genetically engineered models supporting Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative disorders. "Our goal is to provide researchers with translationally relevant models aged appropriately for experimental-readiness, to answer increasingly complex scientific questions," added Sterlace. "These new additions strengthen our Alzheimer's disease portfolio and reinforce Taconic's commitment to supporting translational neuroscience research." The new APOE3xAPP/PS1 (ARTE10) and APOE4xAPP/PS1 (ARTE10) models will be available for research use beginning August 21, 2026. "Alzheimer's disease is not a single disease mechanism, and no single preclinical model can answer every research question. By combining established amyloid pathology with human APOE genetics, these new models give researchers additional tools to evaluate therapeutic efficacy across more clinically relevant disease biology." Sarah Sterlace, PhD, Senior Director, Neurobiology Portfolio Management, Taconic Biosciences About Taconic Biosciences Taconic Biosciences is a global leader in genetically engineered rodent models and associated services, providing innovative research models and scientific expertise to accelerate drug discovery. For more than 70 years, Taconic has partnered with pharmaceutical and biotechnology companies, academic institutions, and government organizations worldwide to advance biomedical research through industry-leading animal models, custom model generation, breeding, colony management, and scientific services. Media Contact: Travis LaFavor Director, Marketing Operations, Taconic Biosciences [email protected]